Zydus receives EIR for oncology injectable manufacturing facility in SEZ1, Ahmedabad

Zydus Lifesciences Ltd has received the Establishment Inspection Report (EIR) and approval letter from the USFDA for the Pre-Approval Inspection (PAI) conducted at SEZ oncology injectable manufacturing site in SEZ1, Ahmedabad, in relation to the new isolator injectable line. The inspection was conducted from 4th to 13th November, 2025.

Shares of Zydus Lifesciences Limited was last trading in BSE at Rs. 936.00 as compared to the previous close of Rs. 923.10. The total number of shares traded during the day was 46350 in over 2900 trades.

The stock hit an intraday high of Rs. 937.65 and intraday low of 920.00. The net turnover during the day was Rs. 43172366.00.

Source : Equity Bulls

Keywords

ZydusLifesciences INE010B01027 Pharmaceuticals EIR USFDA PAI